CHELMSFORD, Mass. — Asahi Kasei, a global leader in healthcare technology and pharmaceutical solutions, announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval for ZOLL’s Zenix monitor/defibrillator. The newly approved device represents ZOLL’s most advanced and user-friendly professional monitor/defibrillator to date, incorporating years of clinician feedback to improve performance and ease of use in emergency and hospital environments.
Designed for both EMS and hospital applications, the Zenix monitor/defibrillator features a large, durable touchscreen, intuitive interface, and workflow automation capabilities that allow real-time customization during critical situations. The device also integrates ZOLL’s proprietary Real BVM Help and Real CPR Help technologies, providing dynamic guidance to support healthcare providers in delivering high-quality resuscitation care.
ZOLL, a key subsidiary of Asahi Kasei, has been a major driver of growth in the company’s Healthcare sector, contributing to a fivefold increase in net sales and a sevenfold rise in operating income since joining the Asahi Kasei Group in 2012. The company’s medium-term management plan emphasizes continued innovation and the introduction of high-value medical technologies to maintain competitiveness in the global market. The Zenix monitor/defibrillator exemplifies this strategy by combining advanced functionality with user-centered design.
“The approval of Zenix reflects our strategic, long-term focus on growth through high-value, solution-based technologies,” said Ken Shinomiya, Leader of the Healthcare Sector at Asahi Kasei. “This device has been designed with an understanding of customer needs, and we expect it will be well-received by customers and healthcare professionals. This innovation expands our critical care portfolio and offers healthcare providers an excellent tool to tackle their key challenges. We will stay competitive and reinforce our commitment to long-term profitable growth through these innovations.”
